What are the opportunities for Indiana's research universities based on what we've learned over the last eighteen months?
Also hear from: Aunalytics, Cook Medical, Elanco, Genezen, Greenlight Guru, HC1.com, Indiana Clinical and Translational Sciences Institute, Roche Diagnostics, University of Notre Dame, WCG Trifecta, and more.
CICP and its subsidiaries are committed to providing a safe, productive, and welcoming environment for all meeting participants and CICP staff.
As such, please remember that any and all policies and expectations regarding professional and respectful conduct and communications apply to virtual meetings and events in the same manner as they do with in-person sessions.
All participants, including, but not limited to, attendees, speakers, volunteers, exhibitors, CICP staff members, service providers, and all others are expected to participate in a professional and respectful manner at all times. This expectation applies to all CICP meeting-related events, including those sponsored by organizations other than CICP but held in conjunction with CICP events, on public or private platforms.
CICP has zero tolerance for any form of discrimination or harassment, including but not limited to sexual harassment by participants or our staff at our meetings or at any other time. If you experience harassment or witness or receive information regarding incidents of unacceptable behavior, CICP asks that you inform Mary Lach-Blake, CICP senior manager of human resources, email@example.com or 317-532-4789 so that we can take the appropriate action.
Although CICP’s expectations in this regard are clear, below please find an inexhaustive list of some examples of prohibited behavior:
CICP reserves the right to take any action deemed necessary and appropriate, including immediate removal from the meeting without warning or refund, in response to any incident of unacceptable behavior, and CICP reserves the right to prohibit attendance at any future meeting, virtually or in person.
You must agree to the code of conduct in-order to proceed to the webpage.
Dan Peterson is Vice President, Industry & Government Affairs for Cook Group Incorporated based in Bloomington, Indiana. Since joining Cook in 1989, Dan has held a variety of leadership roles in the areas of operations, finance and human resources. Dan’s current responsibilities involve industry, government and external affairs. His primary areas of focus center on policies and programs in healthcare, education, economic and workforce development and community engagement.
Dan earned a BS in Biology from Indiana University in 1984 and an MBA in Finance also from Indiana University in 1989.
Dan serves on the Board of Directors for a variety of organizations throughout Indiana including BioCrossroads (board chairman), Indiana Health Industry Forum (emeritus member and former chair), Regional Opportunities Initiative, Inc., and the Bloomington Economic Development Corporation. Dan serves as chairman of the South Central Region Board of Directors of Indiana University Health, and is one of the founding board members for the Indiana Bioscience Research Institute. Dan also serves as a commissioner of the Indiana Commission for Higher Education and is a past chairman.
Since 1963 Cook Group companies are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. Cook Group companies employ more than 12,000 people globally with operations in North America, Europe and Asia-Pacific. Today, Cook manufactures more than 16,000 products that serve more than 40 medical specialties in 135 countries.
Patty Martin joined BioCrossroads as the president and CEO in July 2019, an organization that serves as the connective tissue of the industry, convening Indiana’s research institutions, global companies, philanthropic organizations, and government agencies to ignite growth and innovation, accelerate sector success, foster entrepreneurism, and enable collaboration.
A former Eli Lilly and Company executive, she was the chief operating officer of Lilly Diabetes for seven years as well as served as Lilly’s Chief Diversity Officer and Chief Alliance Officer. In her 26-year career at Lilly, she also held leadership roles that included strategy, finance, clinical product development, and investor relations.
Actively involved in Indianan’s life sciences community, Patty serves as a board member of Indiana Biosciences Research Institute, Indiana Health Information Exchange, and Regenstrief Institute.Beyond Indiana, she serves on the boards of CareSource, Inc., Flame Biosciences, Inc., and AN2 Therapeutics.
A graduate of Indiana University, Martin also earned her MBA from the Harvard School of Business.
As director of corporate communications, Kris provides strategic direction, leadership, and implementation of the network's public relations and media relations plans, policies, and tactics. She ensures successful execution of strategic public relations events, news story placement, online and social media presence, and press conferences and leads the media relations effort in collaboration with product line and regional teams. Kris provides creative direction for video content, production and storytelling to engage internal and external stakeholders.
Prior to joining Community, Kris was an award-winning television journalist, earning honors from the National Academy of Television Arts and Sciences, the Associated Press and the Society of Professional Journalists.
A pioneer in medicine and leadership, Freda Lewis-Hall, MD, DFAPA, MFPM has been on the frontlines of healthcare for more than 40 years as a clinician, researcher, and leader in the biopharmaceuticals and life sciences industries. A passionate advocate for health equity and improved outcomes for all patients, she was a regular guest providing practical, easy to understand health advice and consumer health information on national programs such as "Dr. Phil," and "The Doctors," for nearly a decade, and is a regular speaker at consumer and health care conferences.
Dr. Lewis-Hall is widely regarded for expanding outreach to patients, reshaping the focus on patient engagement and inclusion, improving health information and education, and amplifying the voice of the patient within company culture and decision-making. She served in various leadership roles at a number of pharmaceutical companies, most recently as Chief Medical Officer and Executive Vice President, and later Chief Patient Officer, at Pfizer.
Appointed by the Obama Administration in 2010, she recently completed a decade of service on the Board of Governors for the Patient-Centered Outcomes Research Institute (PCORI). Dr. Lewis-Hall currently serves on boards focusing on advancing health outcomes: 1Life Healthcare, Inc., Exact Sciences Corporation, SpringWorks Therapeutics, Davos Alzheimer's Collaborative, The Foundation for the National Institutes of Health, The Milken Institute’s Faster Cures Center, and the Prostate Cancer Foundation.
Dennis Murphy is president and chief executive office of IU Health, the largest integrated healthcare system in Indiana and one of the largest in the country, with over 36,000 employees, $6.5B in revenue, and provides approximately 30% of all care delivered in the state through its 16 hospitals, over 400 clinical sites and a growing number of home-based and telemedicine services.
He joined IU Health in 2013 as chief operating officer and has guided IU Health as it seeks to fulfill its vision of making Indiana one of the healthiest states in the country. This goal will ideally be achieved through the provision of high-quality destination health programs, building value-based care constructs with payors and employers and addressing underlying impediments to health through community health programs. This vision will be driven by a collective culture that fosters purpose, excellence, compassion, and teamwork.
Dennis has spent his career at academic health centers, with previous leadership positions at Northwestern Medicine, University of Chicago Medicine, and Johns Hopkins Hospital.
A native of Chicago, Murphy earned a bachelor of arts degree from University of Notre Dame and a master of healthcare administration degree from Duke University. He is an adjunct faculty member in the Department of Health Policy and Management at Indiana University Richard M. Fairbanks School of Public Health.
Murphy serves on the boards of Indianapolis Chamber of Commerce, 500 Festival, Indiana Hospital Association, IU Health Foundation, Riley Children’s Foundation, Central Indiana Corporate Partnership (CICP), National Bank of Indianapolis, and Indiana Health Information Exchange(IHIE). Murphy has chaired the American Hospital Association’s (AHA)Transparency Task Force since 2019.
Murphy lives in Carmel, IN with his wife and children.
Virginia A. Caine, MD is one of the top doctors for Infectious Diseases in the United States. She is the Director and Chief Medical Officer of the Marion County Public Health Department. She is an Associate Professor of Medicine at Indiana University School of Medicine Infectious Diseases Division. She is an Indiana University Bicentennial professor. She served as the President for American Public Health Association, the nation’s oldest and largest public health organization. She received the BioCrossroads “2017 August M. Watanabe Life Sciences Champion of the Year” Award. In 2020, the Indianapolis Business Journal (IBJ) named her as one of 40 Influential People of the past 40 years, as they celebrated 40 Years of Progressin Indianapolis.
Dr. Caine works tirelessly to promote and advance public health through innovative programs and unprecedented collaborations. Her boundless energy, vision, and drive to serve people, especially disadvantaged areas, have led Dr. Caine to have her fingerprints on numerous projects.
She is Chair of the National Medical Association Infectious Diseases Section, Co-Chair of the NMA HIV/AIDS Section, and member of the National Medical Association COVID-19 Task Force. She is a member of the Indiana COVID Vaccine Allocation and Distribution Workgroup and board member of the CDC Morbidity and Mortality Weekly Report (MMWR) Editorial Board. She is a member of the George W. Counts Interest Group IDSA. She is the Chair of the Indiana University Simon Comprehensive Cancer Center Community Advisory Committee. She chairs the Managed Emergency Surge of Healthcare (MESH) Coalition, a nonprofit public-private partnership addressing emergency preparedness in Marion County, Indiana. She is a past member of the National Biodefense Science Board, which provides guidance to the Secretary of the U.S. Department of Health and Human Services and the Assistant Secretary of Preparedness.
Erhardt Preitauer joined CareSource in May 2018 bringing two decades of transformational leadership and government-sponsored health plan expertise to the role. Erhardt is an accomplished health care executive with a track record of driving significant growth, profitability, innovation and operational excellence. He has extensive experience in building and leading mission-driven health care organizations.
Prior to joining CareSource, he led Horizon New Jersey Health, the state’s largest Medicaid plan, as CEO. During his tenure, the organization served 1 million members and was recognized as one of the fastest-growing Medicaid plans in the country growing its revenue from $2.2 billion to $6.3 billion in the span of three years. Erhardt is a decorated champion of technology and innovation in long term care. Under his direction, the plan earned a #3 ranking in the 2016 InformationWeek Elite 100 and a 2015 Digital Edge 25 distinction.
His career includes leadership positions with a number of prominent health care organizations including Aetna, WellCare Health Plans and UnitedHealth Group.
Erhardt graduated from the University of Nevada with a Bachelor of Science in finance and economics and also holds a Master of Business Administration degree from Penn State University. He is active in the health care industry and currently serves on the board for America’s Health Insurance Plans (AHIP), the Dayton Development Coalition and the Ohio Business Roundtable. He previously served as chairman of the board of directors for the Medicaid Health Plans of America and as a board member of the Institute for Medicaid Innovation.
In June 2019, Erhardt was named by Glassdoor as one of the highest-rated CEOs in the country, ranking #20 on their annual list based on employee reviews. Preitauer was also recognized by Medicaid Health Plans of America in October 2018 with the Joy Wheeler Leadership Award after helping guide that organization to become a leading voice for Medicaid health plans and the beneficiaries they serve.
Richard DiMarchi is a Distinguished Professor of Chemistry and Gill Chair in Biomolecular Sciences at Indiana University, where he previously served as chairman of the Chemistry Department. Dr. DiMarchi is a member of the National Academy of Medicine and the National Inventors Hall of Fame. He is a former Group Vice President at Eli Lilly and later at Novo Nordisk. He is recognized for his contributions to the discovery and development of rDNA-derived Humalog®, rGlucagon®, and Forteo®. His academic research has broadened the understanding of glucagon physiology and the discovery of single molecule multimode agonists for the treatment of diabetes and obesity. He is a former decade-long chairman of the Peptide Therapeutics Foundation and is widely recognized as an international spokesperson for macromolecular medicines.
Professor DiMarchi is co-inventor on more than one hundred U.S. patents and co-author to more than two hundred and fifty peer-reviewed scientific publications. He was identified as atop-five translation researcher by Nature Biotechnology for the years 2014 and 2015. Since 2003, he has co-founded six successful biotech companies (Ambrx, Marcadia, Calibrium, MB2, Assembly, MBX). In the last decade Professor DiMarchi has received the 2011 Merrifield Award for career contributions in peptide sciences, the 2014 German National Erwin Schrödinger-Preis, the 2015 Meienhofer Prize, the 2015 Max Bergmann Medal, and the 2016 ACS Alfred Burger career award in medicinal chemistry.
Anthony Philippakis is the chief data officer of the Broad Institute of MIT and Harvard, and the co-director of the Eric and Wendy Schmidt Center.
He trained as a cardiologist at Brigham and Women’s Hospital, with a focus on rare genetic cardiovascular diseases. At the Broad Institute he is the founding director of the Data Sciences Platform, an organization of over 200 software engineers and computational biologists that develops software for analyzing genomic and clinical data. In addition to his roles at the Broad Institute and Brigham and Women’s Hospital, Philippakis is a venture partner at GV, focusing on machine learning, distributed computing, and genomics.
Philippakis received his M.D. from Harvard Medical School and completed a Ph.D. in biophysics at Harvard. As an undergraduate, he studied mathematics at Yale University, and later completed the Part III (equivalent to M. Phil) in mathematics at Cambridge University.
Peter Kim, M.D., is the Director of the Therapeutics Research Program at the Division of AIDS, National Institute of Allergy and Infectious Diseases
He currently oversees a broad portfolio of research grants and contracts involving diagnostics and therapeutics for HIV, tuberculosis, and other HIV related co-infections. His primary areas of expertise and interest include clinical TB and HIV drug development and treatment strategies, as well as TB biomarkers and diagnostics.
He is a U.S. Board certified Infectious Diseases specialist. He received his bachelors degree in Public Health from the Johns Hopkins University, and his medical degree from the University of Maryland School of Medicine. From there he went on to complete his training in Internal Medicine and Infectious Diseases at the Washington Hospital Center, Georgetown University, in Washington, D.C..
Ajay Nirula, M.D., Ph.D. is Vice President, Immunology for Lilly Research Laboratories (LRL) based at the Lilly Biotechnology Center in San Diego. Dr. Nirula joined Lilly in 2015 and is responsible for discovery research and early phase clinical development in immunology. He has most recently served as the medical leader for Lilly’s work during the COVID pandemic that lead to emergency authorization for multiple therapeutic neutralizing antibodies. Prior to joining Lilly, Dr. Nirula held leadership positions at Amgen and Biogen Idec and was involved in several research programs and regulatory filings spanning diseases such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, and vasculitis.
Dr. Nirula earned his undergraduate degree in molecular biology from UC Berkeley, his MD from UCLA School of Medicine, and his PhD from the University of Texas Southwestern Medical School. He subsequently joined the faculty in the Division of Rheumatology at UCSF Medical Center. He has published extensively in the scientific literature in journals such as New England Journal of Medicine, JAMA, and Nature Immunology.
He and his wife Lisa have four children.
Alan Palkowitz, PhD, started his career as the Indiana Biosciences Research Institute’s (IBRI) President and CEO in September 2020. Dr. Palkowitz has 30 years of experience in drug discovery and development in both industry and academia. He is passionate about translational research and is driven to build a world-class organization that catalyzes activities across the life sciences ecosystem.
In addition to his role at the IBRI, Dr. Palkowitz maintains his roles at the Indiana University (IU) School of Medicine as a senior research professor of medicine, where he directs the IUSM-Purdue TaRget Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) Center.
Prior to joining the faculty at the IU School of Medicine, Dr. Palkowitz served as the vice president of discovery chemistry research and technologies at Eli Lilly and Company, where he worked for 28 years. In his role as vice president, Dr. Palkowitz was responsible for the global small molecule drug discovery strategy and delivery of clinical candidates in disease areas including cancer, diabetes and neurodegenerative disorders.
Additionally, Dr. Palkowitz has served on several prominent advisory committees, including most recently the National Institutes of Health's National Center for Advancing Translational Sciences Advisory Council. He has published numerous research articles and is an inventor on almost 60 US patents. Dr. Palkowitz obtained his PhD in synthetic organic chemistry from the Massachusetts Institute of Technology and his bachelor’s degree in chemistry from the University of California at Berkeley.
Dr. Jay L. Hess serves as Indiana University’s Executive Vice President for University Clinical Affairs and Dean of the School of Medicine—the largest medical school in the United States, with nine campuses, more than 2,000 students, and 6,500 full-time, part-time and volunteer faculty. As one of four executive vice presidents of Indiana University, Dr. Hess is charged with guiding the university’s clinical affairs strategy.
As a physician-scientist, Dr. Hess is driven to improve care for patients and is guided by a commitment to transforming health in Indiana and around the world. Since becoming dean, he has overseen a more than 95 percent increase in research funding from the National Institutes of Health over the past five years, and under his leadership, IU School of Medicine’s major initiatives include:
Before moving to Indiana in 2013, Dr. Hess served for eight years as the Carl V. Weller Professor and chair of the Department of Pathology and professor of pathology and internal medicine at the University of Michigan. He previously served as director of hematopathology at the University of Pennsylvania and as assistant professor of pathology at Washington University School of Medicine.
Dr. Hess earned his medical and doctorate degrees from the Johns Hopkins University School of Medicine and completed residency training in anatomic pathology and fellowships in hematopathology and surgical pathology at Brigham and Women’s Hospital. He holds a certificate in business administration from The Wharton School of the University of Pennsylvania, and a master’s degree in health services administration from the University of Michigan School of Public Health.
Theresa S. Mayer is Purdue University’s executive vice president for research and partnerships and a professor of electrical and computer engineering. She oversees Purdue’s $660 million research enterprise, including Discovery Park, an interdisciplinary complex for grand-challenge research and is responsible for Purdue’s international programs and its global and corporate partnerships endeavors.
Before joining Purdue University, Mayer served as vice president for research and innovation and a professor of electrical and computer engineering at Virginia Tech. Prior to her role at Virginia Tech, Mayer was at Pennsylvania State University for more than 20 years, where she served as a distinguished professor of electrical engineering, associate dean for research and innovation in the College of Engineering, the site director of the National Science Foundation’s National Nanotechnology Infrastructure Network and director of the Materials Research Institute Nanofabrication Laboratory.
She is internationally recognized for her research in applications of nanotechnology to electronic and photonic devices with new and previously unexplored functions. Her work in directed and self-assembly of nanoparticles has been used to expand the types and complexity of materials that can be integrated into devices beyond standard lithographic approaches, enabling a wide range of novel structures from low-power integrated nanosensor circuits to nanostructured gradient index optical components.
She has more than 350 technical publications, invited presentations and tutorials, and holds eight patents. Several of her co-inventions have been transitioned into commercial products. She is a fellow of the Institute for Electrical and Electronics Engineers, and has received numerous awards for her teaching and research, including the NSF CAREER award. Throughout her career, she has supported the advancement of women in science and engineering.
Mayer earned her bachelor’s degree from Virginia Tech, and a master’s degree and Ph.D. in electrical engineering from Purdue.
Marie Lynn Miranda began her tenure as Charles and Jill Fischer Provost of the University of Notre Dame on July 1, 2020, the fifth provost at Notre Dame since the position was established in 1970. The University’s second-ranking officer, the provost is elected by the Board of Trustees and, at the direction of the president, exercises overall responsibility for the academic enterprise.
A distinguished scholar in the field of children’s environmental health, Miranda is especially well-known for her research on childhood lead exposure. She served as provost at Rice University from 2015–19 and as dean of the University of Michigan’s School of Natural Resources and Environment for the four years prior to that.
“As the first American-born member of an immigrant family, I have benefited tremendously from the transformative power of education,” Miranda said when her appointment as Charles and Jill Fischer Provost was announced. “I am grateful on a daily basis for the opportunity that Notre Dame made available to my father, and consequently to my entire family, when he was invited to undertake graduate studies at the University many years ago. I am both deeply honored and excited to serve the Notre Dame community.”
In addition to her responsibilities as provost, Miranda is a professor of applied and computational mathematics and statistics at Notre Dame, maintaining an active research portfolio. She is a leader in the rapidly evolving field of geospatial health informatics and is the founding director of the Children’s Environmental Health Initiative (CEHI), a research, education, and outreach program committed to fostering environments where all people can prosper. Her interest in the joint effects of social and environmental exposures has led her to study the impact on health of racial residential segregation in particular.
Miranda’s research has generated more than $60 million in funding from federal, state and foundation sources, including the United States Environmental Protection Agency (EPA), the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the National Association of Chronic Disease Directors, the United States Department of Agriculture, the Robert Wood Johnson Foundation, and the Environmental Defense Fund, among others. Her research group at CEHI was among the inaugural winners of the EPA’s Environmental Justice Achievement Award in 2008.
As the provost at Rice, Miranda was responsible for developing and implementing plans for $230 million in strategic programmatic investments as well as over $250 million in major renovations of university facilities. She placed an emphasis on the success of first-generation students and those from lower socioeconomic backgrounds, a focus that helped narrow the disparities in graduation rates and time to degree. She also prioritized increasing the gender and racial diversity of the faculty and academic leaders, resulting in substantial increases in underrepresented minority and women faculty.
Miranda spent the first 21 years of her academic career on the faculty at Duke University, her alma mater, during which time she won the university’s top teaching award and founded CEHI.
An elected fellow of the American Association for the Advancement of Science and a member of Sigma Xi, she is an adjunct professor of pediatrics at Duke as well as Baylor College of Medicine. She sits on the boards of the Environmental Defense Fund and the Doris Duke Charitable Foundation and has provided extensive service to the NIH.
Miranda graduated Phi Beta Kappa, summa cum laude from Duke with a bachelor’s degree in mathematics and economics and was named a Truman Scholar. She received her master’s and doctorate from Harvard University, where she held a National Science Foundation Graduate Research Fellowship. Her father, Constancio Miranda, earned his master’s in civil engineering from Notre Dame in 1962.
Miranda and her husband, Chris Geron, have three children.